The increase in NUPLAZID sales was attributed to growth in unit sales and a higher average net selling price, while DAYBUE's sales growth was primarily due to increased unit sales. Geographical Performance : All revenues for the three months ended March 31, 2025, were generated from customers in North America, indicating a strong regional focus and market presence. Sales Units : The increase in net product sales for both NUPLAZID and DAYBUE was driven by growth in unit sales, reflecting strong market demand and effective sales strategies. Future Outlook : The company plans to continue developing its current portfolio, expand its pipeline of early- and late-stage product candidates, and explore strategic business development opportunities. It also aims to initiate additional studies for ACP-204 in Lewy Body Dementia with Psychosis in the third quarter of 2025 and expects to start a Phase 2 study for ACP-711 in 2026.